« Back
Home /
Erlotinib

Erlotinib

Item no.	HY-50896-1g
Manufacturer	MedChem Express
CASRN	183321-74-6
Amount	1 g
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg
Category	Oncology Neuroscience Metabolism Diabetes Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.\|[2]Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7(6), 1708-1719.\|[3]Wada Y, et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One. 2014 Nov 12;9(11):e111728. Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Adv Ther. 2024 Jul 18.\|Anal Chim Acta. 2018 Nov 22;1032:138-146.\|Bioact Mater. 2021 Nov 4;13:312-323.\|Bioact Mater. 2024 May 11:38:384-398.\|Biochem Biophys Res Commun. 20 October 2022.\|Biochem Biophys Res Commun. 2024 Sep 19:733:150711.\|Biol Methods Protoc. 2025 Feb 13.\|Biomaterials. 16 September 2022.\|Biomed Chromatogr. 2016 Jul;30(7):1150-4. \|Biomed Chromatogr. 2024 Nov 7:e6039.\|Biomed Pharmacother. 2024 Apr 30:175:116644.\|Biomed Res Int. 2019 Nov 28;2019:2410845.\|bioRxiv. 2019 Sep.\|bioRxiv. 2023 Oct 20:2023.10.19.563158.\|bioRxiv. 2024 Dec 20:2024.12.19.629301.\|bioRxiv. October 28, 2021.\|Br J Cancer. 2022 Dec 7.\|Breast Cancer Res Treat. 2025 Mar 7.\|Cancer Manag Res. 2024 May 28:16:507-525.\|Cancer Med. 2019 Dec;8(18):7793-7808.\|Cancer Med. 2024 May;13(10):e7083.\|Cancer Res Treat. 2023 Jan 26.\|Cancer Res Treat. 2023 Jun 12.\|Cancer Res. 2023 Dec 14.\|Cancers (Basel). 2022 Jun 5;14(11):2807.\|Cell Biol Toxicol. 2020 Jun 13.\|Cell Death Differ. 2024 May 30.\|Cell Death Dis. 2022 Dec 27;13(12):1075.\|Cell Death Dis. 2022 Jan 13;13(1):55.\|Cell Insight. 16 June 2022, 100045.\|Cell Rep Med. 2023 Jan 10;100911.\|Cell Rep. 2024 Mar 27;43(4):114002.\|Cell Res. 2020 Oct;30(10):833-853. \|Cell Syst. 2020 Nov 18;11(5):478-494.e9.\|Commun Biol. 2021 Dec 13;4(1):1391.\|Ecotoxicol Environ Saf. 2022 Dec 9;249:114386.\|Ecotoxicol Environ Saf. 2024 Sep 27:285:117031.\|EMBO J. 2025 Jan 21.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Exp Cell Res. 2021 Feb 1;399(1):112424.\|Front Pharmacol. 2018 Jun 21;9:660. \|Front Pharmacol. 2022 Apr 8;13:879751.\|Genome Med. 2021 Sep 1;13(1):142.\|Harvard Medical School LINCS LIBRARY\|Int J Biol Macromol. 2023 Aug 4;126147.\|J Cancer. 2024 Mar 25; 15(10):2891-2899.\|J Cell Mol Med. 2020 Jan;24(2):1969-1979.\|J Clin Invest. 2020 Mar 2;130(3):1417-1430.\|J Control Release. 2024 Nov 5:376:829-841.\|J Exp Clin Cancer Res. 2021 Jan 9;40(1):25.\|J Exp Clin Cancer Res. 2024 Nov 20;43(1):308.\|J Invest Dermatol. 2019 Jan;139(1):224-234.\|J Med Food. 2018 Jul;21(7):701-708.\|J Nutr Biochem. 2023 Jun 2;109399.\|J Pharm Anal. 2021 Jun 19.\|Lung Cancer. 2024 Apr 11.\|Mar Drugs. 2024 Sep 28;22(10):444.\|Mol Cancer Res. 2019 Nov;17(11):2233-2243.\|Mol Carcinog. 2022 Apr 13.\|Mol Cell. 2022 May 14;S1097-2765(22)00434-8.\|Mol Cell. 2023 Dec 7;83(23):4334-4351.e7.\|Mol Divers. 2024 Oct 2.\|Mol Oncol. 2018 Mar;12(3):305-321.\|Mol Oncol. 2023 Jul 27.\|Mol Pharm. 2021 Jun 2.\|Nat Commun. 2023 Apr 24;14(1):2342.\|Nat Commun. 2023 Mar 28;14(1):1726.\|Nat Commun. 2019 Apr 18;10(1):1812\|Neurobiol Dis. 2020 Aug;142:104961.\|Oncogene. 2017 May 11;36(19):2643-2654.\|Oncogene. 2021 Jul;40(30):4884-4893.\|Oncogene. 2021 Mar 9.\|Oncogene. 2022 May;41(22):3064-3078.\|Oncogene. 2023 Aug 17.\|Oncol Rep. 2016 Dec;36(6):3588-3596.\|Oncol Rep. 2021 Jan 22.\|Oncotarget. 2017 Dec 2;8(68):112313-112329.\|Patent. US20240344020A1\|Patent. US20240344020A1.\|Pharmaceuticals (Basel). 2024 Dec 16;17(12):1696.\|PLoS One. 2018 Jun 14;13(6):e0199208.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|PLoS Pathog. 2024 Aug 5;20(8):e1012437.\|Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121.\|Proteomes. 2023 Jun 2, 11(2), 20.\|Research Square Preprint. 2021 May.\|Research Square Preprint. 2022 Jun.\|Research Square Preprint. 2024 Nov 26.\|Saudi Pharm J. 2023 Aug 24, 101756.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|SSRN. 31 Aug 2021.\|Stem Cell Res Ther. 2022 Jun 21;13(1):269.\|Stem Cells. 2022 May 27;40(5):508-522.\|Thorac Cancer. 2020 Oct;11(10):2858-2866.\|Virulence. 2022 Dec;13(1):1849-1867.\|Viruses. 2020 Jun 10;12(6):628.\|Am J Transl Res. 2020 May 15;12(5):2295-2304. \|cell rep methods. 2023 Feb 27.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell Rep. 2023 May 29;42(6):112570.\|CNS Neurosci Ther. 2021 Nov 2.\|Nat Immunol. 2022 Feb;23(2):251-261.
Smiles	C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CP-358774,NSC 718781,OSI-774
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; EGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	393.44
Product Description	Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 3.94 mg/mL (ultrasonic; warming; heat to 40°C)
Manufacturer - Pathway	Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Isoform	EGFR/ErbB1/HER1
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50896-1g-safety-datasheet.pdf